Press Enter to search · Esc to close
A new post-hoc analysis tracks inflammatory and immune markers in adults with type 2 diabetes for two years on a carb-restricted, ketogenic plan — and the signal goes well beyond blood sugar.
Endocrinologists are quietly rewriting the rulebook — treating diabetes, fatty liver, and heart disease as one slow-burning inflammatory story. Here's what that means for the rest of us.
New meta-analyses suggest the metabolic-drug story is moving past the scale — toward measurable inflammation reduction and stacked cardiorenal protection. Here's what that actually changes for a 40-year-old.
A new NHANES analysis suggests a simple index pulled from a routine CBC — the Systemic Immune-Inflammatory Index — tracks with mortality risk in metabolic syndrome. Here's what it is, and what it isn't.
A new composite index built from C-reactive protein, triglycerides and glucose tracked 7,280 adults for nearly a decade — and outperformed its parts at flagging who progressed.
Early science suggests the metabolic chaos behind type 2 diabetes may also drive memory loss and silent artery damage — and that treating one upstream signal could ripple downstream.
A Riyadh case-control study paired with a fresh meta-analysis sharpens the dietary case against fast food in inflammatory bowel disease — and gives busy men a concrete lever to pull.
Two new papers reframe age-related muscle loss as a downstream effect of chronic inflammation, immune aging, and a restless gut. Protein shakes alone won't cut it.
A new mediation analysis points to E-selectin, a marker of blood-vessel stress, as a quiet link between metabolic risk and insulin resistance — while CRP, the inflammation test most of us know, came up short.
Two new studies sharpen the picture of chronic low-grade inflammation in aging — one points to a routine blood ratio, the other to a specific gut microbe coaxed by ginseng. Neither is a prescription. Both are worth watching.